Last reviewed · How we verify
Treatment of Mastocytosis with an Associated Hematological Neoplasm — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| (Part C) MET097 | part-c-met097 | Pfizer | Unknown | Unknown |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Treatment of Mastocytosis with an Associated Hematological Neoplasm
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Treatment of Mastocytosis with an Associated Hematological Neoplasm:
- Treatment of Mastocytosis with an Associated Hematological Neoplasm treatment updates — RSS
- Treatment of Mastocytosis with an Associated Hematological Neoplasm treatment updates — Atom
- Treatment of Mastocytosis with an Associated Hematological Neoplasm treatment updates — JSON
Cite this brief
Drug Landscape (2026). Treatment of Mastocytosis with an Associated Hematological Neoplasm — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-of-mastocytosis-with-an-associated-hematological-neoplasm. Accessed 2026-06-10.
Related
- Treatment of Mastocytosis with an Associated Hematological Neoplasm full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing